Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Post-ASCT in High-Risk DLBCL
NCT00169169Phase 3Terminated
- Sponsor
- Lymphoma Study Association
- Start
- Oct 1999
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Lymphoma Study Association. Started Oct 1999; status: terminated.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00169169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00169169.